• Arnold Louie, Michael T Boyne, Vikram Patel, Clayton Huntley, Weiguo Liu, Steven Fikes, Stephanie Kurhanewicz, Jaime Rodriquez, Nichole Robbins, David Brown, Dodge Baluya, and G L Drusano.
• Institute for Therapeutic Innovation, University of Florida College of Medicine, Orlando, Florida, USA Arnold.Louie@medicine.ufl.edu.
• Antimicrob. Agents Chemother. 2015 Jan 1; 59 (1): 622-32.

AbstractA recent report found that generic parenteral vancomycin products may not have in vivo efficacies equivalent to those of the innovator in a neutropenic murine thigh infection model despite having similar in vitro microbiological activities and murine serum pharmacokinetics. We compared the in vitro and in vivo activities of six of the parenteral vancomycin products available in the United States. The in vitro assessments for the potencies of the vancomycin products included MIC/minimal bactericidal concentration (MBC) determinations, quantifying the impact of human and murine serum on the MIC values, and time-kill studies. Also, the potencies of the vancomycin products were quantified with a biological assay, and the human and mouse serum protein binding rates for the vancomycin products were measured. The in vivo studies included dose-ranging experiments with the 6 vancomycin products for three isolates of Staphylococcus aureus in a neutropenic mouse thigh infection model. The pharmacokinetics of the vancomycin products were assessed in infected mice by population pharmacokinetic modeling. No differences were seen across the vancomycin products with regard to any in vitro evaluation. Inhibitory sigmoid maximal bacterial kill (Emax) modeling of the relationship between vancomycin dosage and the killing of the bacteria in mice in vivo yielded similar Emax and EC50 (drug exposure driving one-half Emax) values for bacterial killing. Further, there were no differences in the pharmacokinetic clearances of the 6 vancomycin products from infected mice. There were no important pharmacodynamic differences in the in vitro or in vivo activities among the six vancomycin products evaluated. Copyright © 2015, American Society for Microbiology. All Rights Reserved.

27 keywords...

hide…